Morgan Stanley reports 4.7% ProKidney stake

Morgan Stanley and an affiliate reported their current ownership in ProKidney Corp. Class A common stock on a Schedule 13G/A amendment.

Rhea-AI Filing Summary

Morgan Stanley and an affiliate reported their current ownership in ProKidney Corp. Class A common stock on a Schedule 13G/A amendment. Morgan Stanley reported aggregate beneficial ownership of 9,653,756 shares with 4.7% of the class, all through shared voting and dispositive power. Morgan Stanley Investment Management Inc. reported beneficial ownership of 9,642,992 shares, also representing 4.7% of the class, with no sole voting or dispositive power. Both entities stated that, as of the reporting date, each has ceased to be the beneficial owner of more than five percent of this class of securities.

Key Figures

Morgan Stanley beneficial ownership: 9,653,756 shares Morgan Stanley Investment Management ownership: 9,642,992 shares Ownership percentage: 4.7% +2 more

5 metrics

Morgan Stanley beneficial ownership 9,653,756 shares Total ProKidney Class A shares beneficially owned by Morgan Stanley

Morgan Stanley Investment Management ownership 9,642,992 shares Total ProKidney Class A shares beneficially owned by Morgan Stanley Investment Management Inc.

Ownership percentage 4.7% Percent of ProKidney Class A common stock beneficially owned by each reporting person

Shared voting power (Morgan Stanley) 9,349,605 shares ProKidney shares over which Morgan Stanley has shared voting power

Shared dispositive power (Morgan Stanley) 9,646,889 shares ProKidney shares over which Morgan Stanley has shared dispositive power

Key Terms

beneficial owner, shared voting power, shared dispositive power, Schedule 13G

4 terms

beneficial owner financial

"has ceased to be the beneficial owner of more than five percent"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power financial

"Shared Voting Power 9,349,605.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 9,646,889.00"

Schedule 13G regulatory

"this filing reflects the securities beneficially owned ... of Morgan Stanley"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ProKidney (PROK) stake does Morgan Stanley currently report?

Morgan Stanley reports beneficial ownership of 9,653,756 ProKidney Class A shares, representing 4.7% of the class, held entirely through shared voting and shared dispositive power, with no sole power over any shares.

What ProKidney (PROK) stake does Morgan Stanley Investment Management report?

Morgan Stanley Investment Management Inc. reports beneficial ownership of 9,642,992 ProKidney Class A shares, representing 4.7% of the class, with no sole voting or dispositive power and all authority classified as shared.

Has Morgan Stanley remained a 5% beneficial owner of ProKidney (PROK)?

No. Both Morgan Stanley and Morgan Stanley Investment Management Inc. state that, as of the reporting date, each has ceased to be the beneficial owner of more than five percent of ProKidney’s Class A common stock.

What voting power does Morgan Stanley report over ProKidney (PROK) shares?

Morgan Stanley reports 0 shares with sole voting power and 9,349,605 shares with shared voting power in ProKidney’s Class A common stock, reflecting joint authority rather than individual control.

Where is ProKidney (PROK) headquartered according to this filing?

ProKidney Corp.’s principal executive offices are listed at 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103, providing the official corporate address for the issuer’s headquarters in this ownership report.

Are Morgan Stanley and its affiliate U.S. entities in this ProKidney (PROK) filing?

Yes. Both Morgan Stanley and Morgan Stanley Investment Management Inc. are organized in Delaware, with principal business offices at 1585 Broadway, New York, NY 10036, as disclosed in the ownership report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 03:45 PM Accepted by SEC EDGAR 08/12/2026 - 03:45 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

PROKIDNEY CORP.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

74291D104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74291D104

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,349,605.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,646,889.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,653,756.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

CUSIP Number(s): 74291D104

1

Names of Reporting Persons

Morgan Stanley Investment Management Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,338,841.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,642,992.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,642,992.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

IA, CO

Comment for Type of Reporting Person: As of the date hereof, Morgan Stanley Investment Management Inc. has ceased to be the beneficial owner of more than five percent of the class of securities.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PROKIDNEY CORP.
(b)	Address of issuer's principal executive offices: 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM, NC, 27103
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Investment Management Inc.
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Class A Common Stock
(e)	CUSIP No.: 74291D104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 4.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Claire Gordon
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/12/2026

Morgan Stanley Investment Management Inc.

Signature:	Deidre A. Downes
Name/Title:	Authorized Signatory, Morgan Stanley Investment Management Inc.
Date:	08/12/2026

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).